NMPA Center for Medical Device Standardization Administration Issued the draft national standard “Post-Market Surveillance for Medical Device Manufacturers” on July 19, 2024, for feedback. Feedback needs to be submitted by September 18.
The document is equivalent to ISO/TR 20416:2020, which refers to ISO 13485 and ISO 14971, acknowledging the global nature of the medical device industry.
For our white paper on China device PMS and periodic risk evaluation report, please click HERE
For our recorded webinar on the latest PMS QMS requirements, please click HERE
For our comprehensive review of the “Guideline for On-Site Inspection of Medical Device Operation Quality Management”, click HERE
The document extensively discusses the regulatory framework, responsibilities, and best practices that medical device manufacturers in China must adhere to after their products have been launched into the market. Below is a detailed summary:
Introduction to Post-Market Surveillance (PMS)
The document begins by stressing the critical importance of post-market surveillance in the lifecycle of a medical device. While pre-market testing, including clinical trials, is crucial for establishing the safety and efficacy of a device, real-world usage can reveal issues that were not evident during controlled testing. Post-market surveillance serves as a proactive approach to identify, monitor, and mitigate these issues, ensuring that the device continues to meet safety standards throughout its lifecycle.
Regulatory Framework in China
The document provides an overview of the regulatory landscape governing PMS in China. The China National Medical Products Administration (NMPA) has established stringent guidelines that medical device manufacturers must follow. These regulations are designed to ensure that devices remain safe and effective for use even after they have been released into the market. The document discusses the specific requirements for different classes of medical devices, highlighting the varying levels of scrutiny based on the device’s risk classification.
PMS Activities and Responsibilities
Medical device manufacturers are required to establish a comprehensive PMS system. This includes the systematic collection, analysis, and interpretation of data related to the performance of the device. The document outlines several key PMS activities, including:
- Adverse Event Reporting: Manufacturers must have a robust system for detecting, reporting, and responding to adverse events associated with their devices. This includes both mandatory reporting to regulatory bodies and voluntary reporting mechanisms.
- Periodic Safety Update Reports (PSURs): These reports are necessary for providing an ongoing assessment of the benefit-risk profile of the device. PSURs must be submitted at regular intervals as specified by the NMPA.
- Post-Market Clinical Follow-Up (PMCF): For certain high-risk devices, manufacturers may need to conduct ongoing clinical studies to gather additional safety and performance data. The document details the requirements for PMCF, including study design and reporting obligations.
Risk Management in PMS
Effective risk management is a cornerstone of PMS. The document highlights the need for manufacturers to continually assess and manage risks associated with their devices. It discusses the methodologies for risk assessment, including failure mode and effects analysis (FMEA) and fault tree analysis (FTA). The document also emphasizes the importance of updating the risk management file throughout the device’s lifecycle, particularly when new information is obtained through PMS activities. Corrective and preventive actions (CAPAs) should be implemented promptly when risks are identified.
Manufacturer Obligations and Compliance
The document outlines the obligations of medical device manufacturers in maintaining compliance with PMS requirements. Key responsibilities include:
- Establishment of a PMS System: Manufacturers must design and implement a PMS system tailored to their specific devices and the markets in which they operate. This system should be documented and regularly reviewed.
- Documentation and Reporting: All PMS activities must be thoroughly documented, including adverse event reports, PSURs, and PMCF studies. Manufacturers are required to maintain detailed records and ensure that they are readily available for inspection by regulatory authorities.
- Timely Reporting: The document emphasizes the importance of timely reporting of adverse events and submission of PSURs. Delays in reporting can result in regulatory actions, including fines or the withdrawal of the device from the market.
Challenges in PMS Implementation
The document discusses several challenges that manufacturers may face in implementing effective PMS systems. These include resource constraints, particularly for small and medium-sized enterprises (SMEs), and the complexity of managing data from multiple sources. The document suggests strategies for overcoming these challenges, such as leveraging technology for data collection and analysis, and collaborating with third-party organizations for specialized PMS activities.
Case Studies and Examples
To provide practical insights, the document includes case studies of medical devices that encountered issues post-market:
Appendix A: Data Source Examples
Data sources include but are not limited to customer complaints, service reports, regulatory authority feedback, scientific literature, and clinical data. Additional guidance on specific data sources can be found in the GHTF document’s Appendix B.
Appendix B: Data Analysis Methods Examples
Key methods include trend analysis, histogram, pareto analysis and qualitative techniques, etc.
Appendix C: PMS Plan Examples
Example devices include surgical scalpels, radiotherapy systems and drug-eluting stents.
For an English copy of the full document, please email us at info@ChinaMedDevice.com.